Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.

In clinical trials, short-term galantamine treatment produces consistent positive effects on global ratings, cognitive tests, and assessments of activities of daily living and behavior in patients with mild-to-moderate Alzheimer's disease (AD), providing the rationale for longer-term, open-labe...

Bibliográfalaš dieđut
Váldodahkkit:	Pirttilä, T, Wilcock, G, Truyen, L, Damaraju, C
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2004

Geahča maid

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
Dahkki: Wilcock, G, et al.
Almmustuhtton: (2000)

Safety and efficacy of galantamine in subjects with mild cognitive impairment.
Dahkki: Winblad, B, et al.
Almmustuhtton: (2008)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial (vol 321, pg 1445, 2000)
Dahkki: Wilcock, G
Almmustuhtton: (2001)

Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data
Dahkki: Wilcock, G, et al.
Almmustuhtton: (2002)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Dahkki: Wilcock, G, et al.
Almmustuhtton: (2003)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9) (1445-1449))
Dahkki: Wilcock, G
Almmustuhtton: (2001)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))
Dahkki: Wilcock, G
Almmustuhtton: (2001)

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
Dahkki: Schmidt Luisa, et al.
Almmustuhtton: (2010-04-01)

Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies
Dahkki: Wilcock, G, et al.
Almmustuhtton: (2002)

Galantamine in Alzheimer's disease.
Dahkki: Razay, G, et al.
Almmustuhtton: (2008)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Dahkki: Ben Seltzer
Almmustuhtton: (2009-12-01)

A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: An intent-to-treat analysis
Dahkki: Wilcock, G, et al.
Almmustuhtton: (2003)

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Dahkki: Wilcock, G, et al.
Almmustuhtton: (2008)

The beneficial effects of galantamine on caregiver time in Alzheimer's disease
Dahkki: Sano, M, et al.
Almmustuhtton: (2003)

The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Dahkki: Sano, M, et al.
Almmustuhtton: (2003)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
Dahkki: Dan-Dan Li, et al.
Almmustuhtton: (2019-05-01)

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
Dahkki: Hossein Pakdaman, et al.
Almmustuhtton: (2015-03-01)

Galantamine vs donepezil in the treatment of Alzheimer's disease.
Dahkki: Goldlist, B, et al.
Almmustuhtton: (2003)

Galantamine treatment in Alzheimer&#39;s disease: response and long-term outcome in a routine clinical setting
Dahkki: Wallin &Aring;K, et al.
Almmustuhtton: (2011-09-01)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
Dahkki: Yi-Ting Lin, et al.
Almmustuhtton: (2019-05-01)

Effect of galantamine on time to residential or nursing home admission
Dahkki: Feldman, H, et al.
Almmustuhtton: (2004)

CLINICAL EFFICACY AND SAFETY OF AND A-2 ANTAGONIST EPROSARTAN IN PATIENTS WITH MILD AND MODERATE HYPERTENSION. RESULTS OF A MULTICENTER TRIAL
Dahkki: L. I. Olbinskaya, et al.
Almmustuhtton: (2001-06-01)

Can we predict the response to Galantamine in Alzheimer`s disease patients?
Dahkki: Carmen Gavan, et al.
Almmustuhtton: (2015-09-01)

Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Dahkki: Mihály Hajós, et al.
Almmustuhtton: (2024-03-01)

A multicenter, open-label study of the efficacy and safety of telmisartan in mild to moderate hypertensive patients
Dahkki: Plavnik Frida Liane, et al.
Almmustuhtton: (2002-01-01)

Design and development of galantamine hydrobromide transdermal patch for treatment of alzheimer’s disease
Dahkki: Woo, Fong Yen
Almmustuhtton: (2015)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
Dahkki: Yasir Hasan Siddique, et al.
Almmustuhtton: (2022-01-01)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
Dahkki: E Loveman, et al.
Almmustuhtton: (2006-01-01)

Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.
Dahkki: Joffres, C, et al.
Almmustuhtton: (2003)

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
Dahkki: Michael F. Egan, et al.
Almmustuhtton: (2019-08-01)

Hierarchical adhesive hydrogel microparticles with galantamine hydrobromide encapsulation for the treatment of Alzheimer’s disease
Dahkki: Huijuan Zhou, et al.
Almmustuhtton: (2024-10-01)

Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension (LTH-1): A multicenter randomized controlled trial
Dahkki: Jiyuan Hui, et al.
Almmustuhtton: (2021-02-01)

Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting
Dahkki: Nakagawa R, et al.
Almmustuhtton: (2017-04-01)

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Dahkki: Marina Ritchie, et al.
Almmustuhtton: (2023-11-01)

Galantamine ameliorates experimental pancreatitis
Dahkki: Dane A. Thompson, et al.
Almmustuhtton: (2023-10-01)

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Dahkki: Kyung Won Park, et al.
Almmustuhtton: (2017-01-01)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
Dahkki: Mohd Adnan, et al.
Almmustuhtton: (2023-09-01)

A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19
Dahkki: Emanuele Nicastri, et al.
Almmustuhtton: (2022-06-01)

New, long-acting form of nifedipine: efficacy and safety in patients with mild to moderate arterial hypertension
Dahkki: E. V. Alimova, et al.
Almmustuhtton: (2004-08-01)

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Dahkki: Brian Lawlor, et al.
Almmustuhtton: (2018-09-01)